Clinical Trials Logo
  1. Home
  2. Breast Tumors
  3. NCT00639171

Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant

Breast Tumors Clinical Trial

Official title:
Clinical Implementation and Evaluation of MR Spectroscopy for Breast Cancer Detection

Clinical Trial Summary

Magnetic Resonance Spectroscopy (MRS) is a novel imaging technique for noninvasive probing of biochemical properties of tissue. While MRS does not generate images of tumor per se it allows biochemical spectroscopic data to be obtained in vivo from user defined region-of-interest. In this manner, biochemical information elucidated by MRS can be interpreted in relation to detailed anatomy and images of metabolite distribution can be created. The aim of MRS is to identify presence and concentration of metabolites characteristic for normal and abnormal (tumor) cellular activities hence allow differential normal tissue from pathological tissue, as well as allow differentiating malignant from benign tumors.

Clinical Trial Description

Recent in vivo studies have reported successful use of 1H and 31P MRS in differentiating between benign and malignant tumors in breast tissue. These studies demonstrated an increase in the choline metabolite peak that reflects an increase in choline-containing metabolites in 70-80% of breast carcinomas, as compared to 14-18% of benign breast tumors.The objectives would be to determine sensitivity/specificity of MRS in the context of breast CA, We will use normal volunteers to test software and to develop and optimize MR scan sequences prior to or during the testing of target subjects with suspicious breast lesion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00639171
Study type Observational
Source State University of New York - Upstate Medical University
Contact
Status Completed
Phase
Start date November 2005
Completion date August 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT02225470 - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Phase 3
Completed NCT01271738 - Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer N/A
Active, not recruiting NCT04132960 - Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis Phase 2
Completed NCT01980823 - Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Early Phase 1
Completed NCT01218529 - Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors Phase 2
Completed NCT02891681 - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment N/A
Terminated NCT01498588 - Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer Phase 2
Recruiting NCT05582499 - Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Phase 1/Phase 2
Completed NCT05584644 - A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
Completed NCT00243698 - A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions N/A
Completed NCT00807859 - Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer Phase 1
Completed NCT01118624 - Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer Phase 2
Recruiting NCT00941408 - Biomarker Study of Breast Tumors N/A
Completed NCT00626106 - QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT01042379 - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase 2
Recruiting NCT05976620 - Clinical Study of 18F-FAPI-RGD in Breast Tumors
Terminated NCT02472353 - Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer Phase 2
Terminated NCT01194908 - Re-expression of ER in Triple Negative Breast Cancers Phase 1/Phase 2
Completed NCT02296801 - A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer Phase 2
Active, not recruiting NCT02187991 - Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Phase 2